Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nordic Prednisolone for Vestibular Neuritis Study
2025-522399-10-00Phase 3Authorised
- Sponsor
- Region Vaesterbotten, Umea University
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, triple-blind trial in vestibular neuritis comparing Prednisolone with Placebo (2 arms). Primary endpoint: Vertigo Symptom Scale short form at 6 weeks. Planned start Jul 2026; status: authorised.
02
Drugs
prednisolone
03
Conditions
vestibular neuritis
Beyond the preview
Go deeper on 2025-522399-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522399-10-00.